Abyssinia Biologics
Trebor Lawton is a seasoned professional in the biotechnology field, currently serving as Co-Founder at Abyssinia Biologics since June 2017, where focus lies on the preclinical development and commercialization of innovative anti-oligomeric Aβ monoclonal antibodies targeting Alzheimer's disease. Previously, Trebor founded Abyssinia Biotechnologies, leading research and development for an OTC screening device aimed at preventing tick-borne diseases and securing funding through Maine Technology Institute grant proposals. Experience includes a role as Laboratory Technician at Aliquot, LLC, specializing in monoclonal antibody development, as well as earlier positions at Niche Diagnostics and Beach Dawgs Hotdog Cart. Trebor holds a Bachelor's degree in Biological Sciences with a concentration in Cellular and Molecular Biology from Connecticut College.
This person is not in any teams
Abyssinia Biologics
Abyssinia is altering the world's understanding of Alzheimer's Disease from diagnostic assays with the potential for early diagnosis to treatment approaches addressing novel disease causes. Abyssinia's lead candidate ABY-71A1 is a IgG1 mAb with a high specificity for toxic soluble amyloid oligomers, which is backed up by ourcompanion diagnostic assay for soluble amyloid in plasma & CSF. Abyssinia was founded in 2017.